Caveolin-1 in oncogenic transformation, cancer, and metastasis

American Journal of Physiology - Cell Physiology

Volumn 288, Issue 3 57-3, 2005, Pages

  Williams, Terence M ^b   Lisanti, Michael P ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

Caveolae; Cell invasiveness; Cellular signaling; Tumor formation

Indexed keywords

CAVEOLIN 1; CAVEOLIN 2; CAVEOLIN 3; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SERINE; TYROSINE;

APOPTOSIS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER; CANCER INHIBITION; CANCER THERAPY; CAVEOLA; CELL CYCLE; CELL TRANSFORMATION; CHROMOSOMAL LOCALIZATION; ENZYME ACTIVATION; GENE MUTATION; GROWTH INHIBITION; HUMAN; METASTASIS; NONHUMAN; ONCOGENE; POINT MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; TUMOR PROMOTION;

ANIMALS; APOPTOSIS; CAVEOLIN 1; CAVEOLINS; CELL CYCLE; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; ONCOGENES; TUMOR SUPPRESSOR PROTEINS;

EID: 13644266312     PISSN: 03636143     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpcell.00458.2004     Document Type: Review

References (134)

1. Aldred MA, Ginn-Pease ME, Morrison CD, Popkie AP, Gimm O, Hoang-Vu C, Krause U, Dralle H, Jhiang SM, Plass C, and Eng C. Caveolin-1 and caveolin-2, together with three bone morphogenetic protein-related genes, may encode novel tumor suppressors down-regulated in sporadic follicular thyroid carcinogenesis. Cancer Res 63: 2864-2871, 2003.
2. Annabi B, Lachambre M, Bousquet-Gagnon N, Page M, Gingras D, and Beliveau R. Localization of membrane-type 1 matrix metalloproteinase in caveolae membrane domains. Biochem J 353: 547-553, 2001.
3. Bagnoli M, Tomassetti A, Figini M, Flati S, Dolo V, Canevari S, and Miotti S. Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to alpha-folate receptor overexpression. Oncogene 19: 4754-4763, 2000.
4. Belanger MM, Gaudreau M, Roussel E, and Couet J. Role of caveolin-1 in etoposide resistance development in A549 lung cancer cells. Cancer Biol Ther 3: 954-959, 2004.
5. Bender FC, Reymond MA, Bron C, and Quest A. Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res 60: 5870-5878, 2000.
6. Benson JR. Role of transforming growth factor beta in breast carcinogenesis. Lancet Oncol 5: 229-239, 2004.
7. Bockhorn M, Roberge S, Sousa C, Jain RK, and Munn LL. Differential gene expression in metastasizing cells shed from kidney tumors. Cancer Res 64: 2469-2473, 2004.
8. Campbell L, Gumbleton M, and Griffiths DF. Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma. Br J Cancer 89: 1909-1913, 2003.
9. Capozza F, Williams TM, Schubert W, McClain S, Bouzahzah B, Sotgia F, and Lisanti MP. Absence of caveolin-1 sensitizes mouse skin to carcinogen-induced epidermal hyperplasia and tumor formation. Am J Pathol 162: 2029-2039, 2003.
10. Carrion R, Morgan BE, Tannenbaum M, Salup R, and Morgan MB. Caveolin expression in adult renal tumors. Urul Oncol 21: 191-196, 2003.
11. Caselli A, Mazzinghi B, Camici G, Manao G, and Ramponi G. Some protein tyrosine phosphatases target in part to lipid rafts and interact with caveolin-1. Biochem Biophys Res Commun 296: 692-697, 2002.
12. Cohen AW, Park DS, Woodman SE, Williams TM, Chandra M, Shirani J, Pereira de Souza A, Kitsis RN, Russell RG, Weiss LM, Tang B, Jelicks LA, Factor SM, Shtutin V, Tanowitz HB, and Lisanti MP. Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts. Am J Physiol Cell Physiol 284: C457-C474, 2003.
13. Couet J, Li S, Okamoto T, Ikezu T, and Lisanti MP. Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins. J Biol Chem 272: 6525-6533, 1997.
14. Couet J, Sargiacomo M, and Lisanti MP. Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J Biol Chem 272: 30429-30438, 1997.
15. Davidson B, Nesland JM, Goldberg I, Kopolovic J, Gotlieb WH, Bryne M, Ben-Baruch G, Berner A, and Reich R. Caveolin-1 expression in advanced-stage ovarian carcinoma - a clinicopathologic study. Gynecol Oncol 81: 166-171, 2001.
16. Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, Menne J, Lindschau C, Mende F, Luft FC, Schedl A, Haller H, and Kurzchalia TV. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 293: 2449-2452, 2001.
17. Engelman JA, Chu C, Lin A, Jo H, Ikezu T, Okamoto T, Kohtz DS, and Lisanti MP. Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain. FEBS Lett 428: 205-211, 1998.
18. Engelman JA, Lee RJ, Karnezis A, Bearss DJ, Webster M, Siegel P, Muller, WJ, Windle JJ, Pestell RG, and Lisanti MP. Reciprocal regulation of Neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for mammary tumorigenesis. J Biol Chem 273: 20448-20455, 1998.
19. Engelman JA, Wykoff CC, Yasuhara S, Song KS, Okamoto T, and Lisanti MP. Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. J Biol Chem 212: 16374-16381, 1997.
20. Engelman JA, Zhang XL, and Lisanti MP. Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS Lett 436: 403-410, 1998.
21. Engelman JA, Zhang XL, Razani B, Pestell RG, and Lisanti MP. p42/44 MAP kinase-dependent and -independent signaling pathways regulate caveolin-1 gene expression. Activation of Ras-MAP kinase and protein kinase A signaling cascades transcriptionally down-regulates caveolin-1 promoter activity. J Biol Chem 274: 32333-32341, 1999.
22. Fine SW, Lisanti MP, Galbiati F, and Li M. Elevated expression of caveolin-1 in adenocarcinoma of the colon. Am J Clin Pathol 115: 719-724, 2001.
23. Fiucci G, Ravid D, Reich R, and Liscovitch M. Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene 21: 2365-2375, 2002.
24. Fong A, Garcia E, Gwynn L, Lisanti MP, Fazzari MJ, and Li M. Expression of caveolin-1 and caveolin-2 in urothelial carcinoma of the urinary bladder correlates with tumor grade and squamous differentiation. Am J Clin Pathol 120: 93-100, 2003.
25. Forget MA, Desrosiers RR, Del M, Moumdjian R, Shedid D, Berthelet F, and Beliveau R. The expression of rho proteins decreases with human brain tumor progression: potential tumor markers. Clin Exp Metastasis 19: 9-15, 2002.
26. Galbiati F, Volonte D, Engelman JA, Watanabe G, Burk R, Pestell RG, and Lisanti MP. Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J 17: 6633-6648, 1998.
27. 1 arrest via a p53/p21(WAF1/Cip1)- dependent mechanism. Mol Biol Cell 12: 2229-2244, 2001.
28. Galvez BG, Matias-Roman S, Yanez-Mo M, Vicente-Manzanares M, Sanchez-Madrid F, and Arroyo AG. Caveolae are a novel pathway for membrane-type 1 matrix metalloproteinase traffic in human endothelial cells. Mol Biol Cell 15: 678-687, 2004.
29. Garcia-Cardena G, Martasek P, Siler-Masters BS, Skidd PM, Couet JC, Li S, Lisanti MP, and Sessa WC. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin: functional significance of the NOS caveolin binding domain in vivo. J Biol Chem 272: 25437-25440, 1997.
30. Glenney JR Jr. Tyrosine phosphorylation of a 22-kDa protein is correlated with transformation by Rous sarcoma virus. J Biol Chem 264: 20163-20166, 1989.
31. Glenney JR Jr and Soppet D. Sequence and expression of caveolin, a protein component of caveolae plasma membrane domains phosphorylated on tyrosine in Rous sarcoma virus-transformed fibroblasts. Proc Natl Acad Sci USA 89: 10517-10521, 1992.
32. Glenney JR Jr and Zokas L. Novel tyrosine kinase substrates from Rous sarcoma virus-transformed cells are present in the membrane skeleton. J Cell Biol 108: 2401-2408, 1989.
33. Gratton JP, Lin MI, Yu J, Weiss ED, Jiang ZL, Fairchild TA, Iwakiri Y, Groszmann R, Claffey KP, Cheng YC, and Sessa WC. Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell 4: 31-39, 2003.
34. Han SE, Park KH, Lee G, Huh YJ, and Min BM. Mutation and aberrant expression of caveolin-1 in human oral squamous cell carcinomas and oral cancer cell lines. Int J Oncol 24: 435-440, 2004.
35. Hatanaka M, Maeda T, Ikemoto T, Mori H, Seya T, and Shimizu A. Expression of caveolin-1 in human T cell leukemia cell lines. Biochem Biophys Res Commun 253: 382-387, 1998.
36. Hayashi K, Matsuda S, Machida K, Yamamoto T, Fukuda Y, Nimura Y, Hayakawa T, and Hamaguchi M. Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res 61: 2361-2364, 2001.
37. Ho CC, Huang PH, Huang HY, Chen YH, Yang PC, and Hsu SM. Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am J Pathol 161: 1647-1656, 2002.
38. Horiguchi A, Asano T, Asakuma J, Sumitomo M, and Hayakawa M. Impact of caveolin-1 expression on clinicopathological parameters in renal cell carcinoma. J Urol 172: 718-722, 2004.
39. Hu YC, Lam KY, Law S, Wong J, and Srivastava G. Profiling of differentially expressed cancer-related genes in esophageal squamous cell carcinoma (ESCC) using human cancer cDNA arrays: overexpression of oncogene MET correlates with tumor differentiation in ESCC. Clin Cancer Res 7: 3519-3525, 2001.
40. Hulit J, Bash T, Fu M, Galbiati F, Albanese C, Sage DR, Schlegel A, Zhurinsky J, Shtutman M, Ben-Ze'ev A, Lisanti MP, and Pestell RG. The cyclin D1 gene is transcriptionally repressed by caveolin-1. J Biol Chem 275: 21203-21209, 2000.
41. Hung KF, Lin SC, Liu CJ, Chang CS, Chang KW, and Kao SY. The biphasic differential expression of the cellular membrane protein, caveolin-1, in oral carcinogenesis. J Oral Pathol Med 32: 461-467, 2003.
42. Ito Y, Yoshida H, Nakano K, Kobayashi K, Yokozawa T, Hirai K, Matsuzuka F, Matsuura N, Kakudo K, Kuma K, and Miyauchi A. Caveolin-1 overexpression is an early event in the progression of papillary carcinoma of the thyroid. Br J Cancer 86: 912-916, 2002.
43. Joo HJ, Oh DK, Kim YS, Lee KB, and Kim SJ. Increased expression of caveolin-1 and microvessel density correlates with metastasis and poor prognosis in clear cell renal cell carcinoma. BJU Int 93: 291-296, 2004.
44. Ju H, Zou R, Venema VJ, and Venema RC. Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity. J Biol Chem 111: 18522-18525, 1997.
45. Kasahara T, Hara N, Bilim V, Tomita Y, Tsutsui T, and Takahashi K. Immunohistochemical studies of caveolin-3 in germ cell tumors of the testis. Urol Int 69: 63-68, 2002.
46. Kato K, Hida Y, Miyamoto M, Hashida H, Shinohara T, Itoh T, Okushiba S, Kondo S, and Katoh H. Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer 94: 929-933, 2002.
47. Kerr J, Leary JA, Hurst T, Shih YC, Antalis TM, Friedlander M, Crawford E, Khoo SK, Ward B, and Chenevix-Trench G. Allelic loss on chromosome 7q in ovarian adenocarcinomas: two critical regions and a rearrangement of the PLANH1 locus. Oncogene 13: 1815-1818, 1996.
48. Koleske AJ, Baltimore D, and Lisanti MP. Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci USA 92: 1381-1385, 1995.
49. Krump-Konvalinkova V, Kleideiter E, Friedrich U, Klotz U, and Kirkpatrick CJ. Tumorigenic conversion of endothelial cells. Exp Mol Pathol 75: 154-159, 2003.
50. Kurzchalia T, Dupree P, Parton RG, Kellner R, Virta H, Lehnert M, and Simons K. VIP 21, A 21-kD membrane protein is an integral component of trans-Golgi-network-derived transport vesicles. J Cell Biol 118: 1003-1014, 1992.
51. Lavie Y and Liscovitch M. A role for caveolae in multidrug resistance of cancer cells (Abstract). Mol Biol Cell 8: 207a, 1997.
52. Lee H, Park DS, Razani B, Russell RG, Pestell RG, and Lisanti MP. Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia. Am J Pathol 161: 1357-1369, 2002.
53. Lee H, Park DS, Wang XB, Scherer PE, Schwartz PE, and Lisanti MP. Src-induced phosphorylation of caveolin-2 on tyrosine 19. Phosphocaveolin-2 [Tyr(P)19] is localized near focal adhesions, remains associated with lipid rafts/caveolae, but no longer forms a high molecular mass hetero-oligomer with caveolin-1. J Biol Chem 277: 34556-34567, 2002.
54. Lee H, Volonte D, Galbiati F, Iyengar P, Lublin DM, Bregman DB, Wilson MT, Campos-Gonzalez R, Bouzahzah B, Pestell RG, Scherer PE, and Lisanti MP. Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-Src/Cav-1/Grb7 signaling cassette. Mol Endocrinol 14: 1750-1775, 2000.
55. Lee H, Woodman SE, Engelman JA, Volonte D, Galbiati F, Kaufman HL, Lublin DM, and Lisanti MP. Palmitoylation of caveolin-1 at a single site (Cys-156) controls its coupling to the c-Src tyrosine kinase: targeting of dually acylated molecules (GPI-linked, transmembrane, or cytoplasmic) to caveolae effectively uncouples c-Src and caveolin-1 (Tyr14). J Biol Chem 276: 35150-35158, 2001.
56. Lee SW, Reimer CL, Oh P, Campbell DB, and Schnitzer JE. Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene 16: 1391-1397, 1998.
57. Li L, Ren CH, Tahir SA, Ren C, and Thompson TC. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol 23: 9389-9404, 2003.
58. Li L, Yang G, Ebara S, Satoh T, Nasu Y, Timme TL, Ren C, Wang J, Tahir SA, and Thompson TC. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res 61: 4386-4392, 2001.
59. Li S, Couet J, and Lisanti MP. Src tyrosine kinases, G alpha subunits and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J Biol Chem 271: 29182-29190, 1996.
60. Li S, Okamoto T, Chun M, Sargiacomo M, Casanova JE, Hansen SH, Nishimoto I, and Lisanti MP. Evidence for a regulated interaction of hetero-trimeric G proteins with caveolin. J Biol Chem 270: 15693-15701, 1995.
61. Lisanti MP, Scherer P, Tang ZL, and Sargiacomo M. Caveolae, caveolin and caveolin-rich membrane domains: a signalling hypothesis. Trends Cell Biol 4: 231-235, 1994.
62. Lisanti MP, Scherer PE, Vidugiriene J, Tang ZL, Hermanoski-Vosatka A, Tu YH, Cook RF, and Sargiacomo M. Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease. J Cell Biol 126: 111-126, 1994.
63. Liu J, Lee P, Galhiati F, Kitsis RN, and Lisanti MP. Caveolin-1 expression sensitizes fibroblastic and epithelial cells to apoptotic stimulation. Am J Physiol Cell Physiol 280: C823-C835, 2001.
64. Liu J, Oh P, Horner T, Rogers RA, and Schnitzer JE. Organized endothelial cell surface signal transduction in caveolae distinct from glycosylphosphatidylinositol-anchored protein microdomains. J Biol Chem 272: 7211-7222, 1997.
65. Liu P and Anderson RGW. Compartmentalized production of ceramide at the cell surface. J Biol Chem 270: 27179-27185, 1995.
66. Liu P, Rudick M, and Anderson RG. Multiple functions of caveolin-1. J Biol Chem 211: 41295-41298, 2002.
67. Liu P, Ying Y, Ko YG, and Anderson RGW. Localization of the PDGF-stimulated phosphorylation cascade to caveolae. J Biol Chem 271: 10299-10303, 1996.
68. Liu P, Ying YS, and Anderson RGW. PDGF activates MAP kinase in isolated caveolae. Proc Natl Acad Sci USA 94: 13666-13670, 1997.
69. Lu Z, Ghosh S, Wang Z, and Hunter T. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell 4: 499-515, 2003.
70. Matsuura K, Shiga K, Yokoyama J, Saijo S, Miyagi T, and Takasaka T. Loss of heterozygosity of chromosome 9p21 and 7q31 is correlated with high incidence of recurrent tumor in head and neck squamous cell carcinoma. Anticancer Res 18: 453-458, 1998.
71. 2+-calmodulin and caveolin. J Biol Chem 272: 15583-15586, 1997.
72. Mineo C, James GL, Smart EJ, and Anderson RGW. Localization of EGF-stimulated Ras/Raf-1 interaction to caveolae membrane. J Biol Chem 271: 11930-11935, 1996.
73. Minetti C, Sotogia F, Bruno C, Scartezzini P, Broda P, Bado M, Masetti E, Mazzocco P, Egeo A, Donati MA, Volonte D, Galbiati F, Cordone G, Bricarelli FD, Lisanti MP, and Zara F. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet 18: 365-368, 1998.
74. Nasu Y, Timme TL, Yang G, Bangma CH, Li L, Ren C, Park SH, DeLeon M, Wang J, and Thompson TC. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat Med 4: 1062-1064, 1998.
75. Nestl A, Von Stein OD, Zatloukal K, Thies WG, Herrlich P, Hofmann M, and Sleeman JP. Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Cancer Res 61: 1569-1577, 2001.
76. Nupponen NN, Kakkola L, Koivisto P, and Visakorpi T. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol 153: 141-148, 1998.
77. Palade GE. Fine structure of blood capillaries. J Appl Physiol 24: 1424-1436, 1953.
78. Park DS, Lee H, Frank PG, Razani B, Nguyen AV, Parlow AF, Russell RG, Hulit J, Pestell RG, and Lisanti MP. Caveolin-1-deficient mice show accelerated mammary gland development during pregnancy, premature lactation, and hyperactivation of the Jak-2/STAT5a signaling cascade. Mol Biol Cell 13: 3416-3430, 2002.
79. Park DS, Razani B, Lasorella A, Schreiber-Agus N, Pestell RG, Iavarone A, and Lisanti MP. Evidence that Myc isoforms transcriptionally repress caveolin-1 gene expression via an INR-dependent mechanism. Biochemistry 40: 3354-3362, 2001.
80. Parolini I, Sargiacomo M, Galbiati F, Rizzo G, Grignani F, Engelman JA, Okamoto T, Ikezu T, Scherer PE, Mora R, Rodriguez-Boulan E, Peschle C, and Lisanti MP. Expression of caveolin-1 is required for the transport of caveolin-2 to the plasma membrane. Retention of caveolin-2 at the level of the Golgi complex. J Biol Chem 274: 25718-25725, 1999.
81. Patlolla JM, Swamy MV, Raju J, and Rao CV. Overexpression of caveolin-1 in experimental colon adenocarcinomas and human colon cancer cell lines. Oncol Rep 11: 957-963, 2004.
82. Pflug BR, Reiter RE, and Nelson JB. Caveolin expression is decreased following androgen deprivation in human prostate cancer cell lines. Prostate 40: 269-273, 1999.
83. Podar K, Tai YT, Cole CE, Hideshima T, Sattler M, Hamblin A, Mitsiades N, Schlossman RL, Davies FE, Morgan GJ, Munshi NC, Chauhan D, and Anderson KC. Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. J Biol Chem 278: 5794-5801, 2003.
84. Pramudji C, Shimura S, Ebara S, Yang G, Wang J, Ren C, Yuan Y, Tahir SA, Timme TL, and Thompson TC. In situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter. Clin Cancer Res 1: 4272-4279, 2001.
85. Puyraimond A, Fridman R, Lemesle M, Arheille B, and Menashi S. MMP-2 colocalizes with caveolae on the surface of endothelial cells. Exp Cell Res 262: 28-36, 2001.
86. Racine C, Belanger M, Hirahayashi H, Boucher M, Chakir J, and Couet J. Reduction of caveolin 1 gene expression in lung carcinoma cell lines. Biochem Biophys Res Commun 255: 580-586, 1999.
87. Rajjayabun PH, Garg S, Durkan GC, Charlton R, Robinson MC, and Mellon JK. Caveolin-1 expression is associated with high-grade bladder cancer. Urology 58: 811-814, 2001.
88. Razani B, Altschuler Y, Zhu L, Pestell RG, Mostov KE, and Lisanti MP. Caveolin-1 expression is down-regulated in cells transformed by the human papilloma virus in a p53-dependent manner. Replacement of caveolin-1 expression suppresses HPV-mediated cell transformation. Biochemistry 39: 13916-13924, 2000.
89. Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, Macaluso F, Russell RG, Li M, Pestell RG, Di Vizio D, Hou H Jr, Kneitz B, Lagaud G, Christ GJ, Edelmann W, and Lisanti MP. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 276: 38121-38138, 2001.
90. Razani B, Woodman SE, and Lisanti MP. Caveolae: from cell biology to animal physiology. Pharmacol Rev 54: 431-467, 2002.
91. Roberts AB and Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 100: 8621-8623, 2003.
92. Rothberg KG, Heuser JE, Donzell WC, Ying YS, Glenney JR, and Anderson RG. Caveolin, a protein component of caveolae membrane coats. Cell 68: 673-682, 1992.
93. Rybin VO, Xu X, and Steinberg SF. Activated protein kinase C isoforms target to cardiomyocyte caveolae: stimulation of local protein phosphorylation. Circ Res 84: 980-988, 1999.
94. Sagara Y, Mimori K, Yoshinaga K, Tanaka F, Nishida K, Ohno S, Inoue H, and Mori M. Clinical significance of caveolin-1, caveolin-2 and HER2/neu mRNA expression in human breast cancer. Br J Cancer 91: 959-965, 2004.
95. Sager R, Sheng S, Anisowicz A, Sotiropoulou G, Zou Z, Stenman G, Swisshelm K, Chen Z, Hendrix MJC, Pemberton P, Rafidi K, and Ryan K. RNA genetics of breast cancer: maspin as a paradigm. Cold Spring Harbor Symp Quant Biol 59: 537-546, 1994.
96. Sanchez-Carbayo M, Socci ND, Charytonowicz E, Lu M, Prystowsky M, Childs G, and Cordon-Cardo C. Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res 62: 6973-6980, 2002.
97. Sargiacomo M, Sudol M, Tang ZL, and Lisanti MP. Signal transducing molecules and GPI-linked proteins form a caveolin-rich insoluble complex in MDCK cells. J Cell Biol 122: 789-807, 1993.
98. Satoh T, Yang G, Egawa S, Addai J, Frolov A, Kuwao S, Timme TL, Baba S, and Thompson TC. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients. Cancer 97: 1225-1233, 2003.
99. Scheel J, Srinivasan J, Honnert U, Henske A, and Kurzchalia TV. Involvement of caveolin-1 in meiotic cell-cycle progression in Caenorhabditis elegans. Nat Cell Biol 1: 127-129, 1999.
100. Scherer PE, Lewis RY, Volonte D, Engelman JA, Galbiati F, Couet J, Kohtz DS, van Donselaar E, Peters P, and Lisanti MP. Cell-type and tissue-specific expression of caveolin-2. Caveolins 1 and 2 colocalize and form a stable hetero-oligomeric complex in vivo. J Biol Chem 272: 29337-29346, 1997.
101. Schlegel A, Arvan P, and Lisanti MP. Caveolin-1 binding to endoplasmic reticulum membranes and entry into the regulated secretory pathway are regulated by serine phosphorylation. Protein sorting at the level of the endoplasmic reticulum. J Biol Chem 276: 4398-4408, 2001.
102. Shridhar V, Sun QC, Miller OJ, Kalemkerian GP, Petros J, and Smith DI. Loss of heterozygosity on the long arm of human chromosome 7 in sporadic renal cell carcinomas. Oncogene 15: 2727-2733, 1997.
103. Siegel PM, Shu W, Cardiff RD, Muller WJ, and Massague J. Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci USA 100: 8430-8435, 2003.
104. Sloan EK, Stanley KL, and Anderson RL. Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene 23: 7893-7897, 2004.
105. Smart EJ, Ying Y, Mineo C, and Anderson RGW. A detergent free method for purifying caveolae membrane from tissue cultured cells. Proc Natl Acad Sci USA 92: 10104-10108, 1995.
106. Song KS, Li S, Okamoto T, Quilliam L, Sargiacomo M, and Lisanti MP. Copurification and direct interaction of Ras with caveolin, an integral membrane protein of caveolae microdomains. Detergent free purification of caveolae membranes. J Biol Chem 271: 9690-9697, 1996.
107. Song KS, Scherer PE, Tang ZL, Okamoto T, Li S, Chafel M, Chu C, Kolitz DS, and Lisanti MP. Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. J Biol Chem 271: 15160-15165, 1996.
108. Sunaga N, Miyajima K, Suzuki M, Sato M, White MA, Ramirez RD, Shay JW, Gazdar AF, and Minna JD. Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Res 64: 4277-4285, 2004.
109. Suzuoki M, Miyamoto M, Kato K, Hiraoka K, Oshikiri T, Nakakubo Y, Fukunaga A, Shichinohe T, Shinohara T, Itoh T, Kondo S, and Katoh H. Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br J Cancer 87: 1140-1144, 2002.
110. Tahir SA, Yang G, Ebara S, Timme TL, Satoh T, Li L, Goltsov A, Ittmann M, Morrisett JD, and Thompson TC. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 61: 3882-3885, 2001.
111. Tang ZL, Scherer PE, Okamoto T, Song K, Chu C, Kohtz DS, Nishimoto I, Lodish HF, and Lisanti MP. Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. J Biol Chem 271: 2255-2261, 1996.
112. Terris B, Blaveri E, Crnogorac-Jurcevic T, Jones M, Missiaglia E, Ruszniewski P, Sauvanet A, and Lemoine NR. Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am J Pathol 160: 1745-1754, 2002.
113. Timme TL, Goltsov A, Tahir S, Li L, Wang J, Ren C, Johnston RN, and Thompson TC. Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis. Oncogene 19: 3256-3265, 2000.
114. Tso CL, McBride WH, Sun J, Patel B, Tsui KH, Paik SH, Gitlitz B, Caliliw R, van Ophoven A, Wu L, deKernion J, and Belldegrun A. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer J 6: 220-233, 2000.
115. Way M and Parton R. M-caveolin, a muscle-specific caveolin-related protein. FEBS Lett 376: 108-112, 1995.
116. Wiechem K, Diatchenko L, Agoulnik A, Scharff KM, Schober H, Arlt K, Zhumabayeva B, Siebert PD, Dietel M, Schafer R, and Sers C. Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol 159: 1635-1643, 2001.
117. Wiechen K, Sers C, Agoulnik A, Arlt K, Dietel M, Schlag PM, and Schneider U. Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas. Am J Pathol 158: 833-839, 2001.
118. Wikman H, Kettunen E, Seppanen JK, Karjalainen A, Hollmen J, Anttila S, and Knuutila S. Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array. Oncogene 21: 5804-5813, 2002.
119. Wikman H, Seppanen JK, Sarhadi VK, Kettunen E, Salmenkivi K, Kuosma E, Vainio-Siukola K, Nagy B, Karjalainen A, Sioris T, Salo J, Hollmen J, Knuutila S, and Anttila S. Caveolins as tumour markers in lung cancer detected by combined use of cDNA and tissue microarrays. J Pathol 203: 584-593, 2004.
120. Williams TM, Cheung MW, Park DS, Razani B, Cohen AW, Muller WJ, Di Vizio D, Chopra NG, Pestell RG, and Lisanti MP. Loss of caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumor-prone transgenic mice. Mol Biol Cell 14: 1027-1042, 2003.
121. Williams TM, Lee H, Cheung MW, Cohen AW, Razani B, Iyengar P, Scherer PE, Pestell RG, and Lisanti MP. Combined loss of INK4a and caveolin-1 synergistically enhances cell proliferation and oncogene-induced tumorigenesis: role of INK4a/CAV-1 in mammary epithelial cell hyperplasia. J Biol Chem 279: 24745-24756, 2004.
122. Williams TM, Medina F, Badano I, Kazan RB, Hutchinson J, Muller WJ, Chopra NG, Scherer PE, Pestell RG, and Lisanti MP. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo: role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem 279: 51630-51646, 2004.
123. Xie Z, Zeng X, Waldman T, and Glazer RI. Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 activates beta-catenin and c-Myc, and down-regulates caveolin-1. Cancer Res 63: 5370-5375, 2003.
124. Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH, Nasu Y, Bangma CH, Kattan MW, Scardino PT, and Thompson TC. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 4: 1873-1880, 1998.
125. Yang G, Truong LD, Wheeler TM, and Thompson TC. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res 59: 5719-5723, 1999.
126. Yoo SH, Park YS, Kim HR, Sung SW, Kim JH, Shim YS, Lee SD, Choi YL, Kim MK, and Chung DH. Expression of caveolin-1 is associated with poor prognosis of patients with squamous cell carcinoma of the lung. Lung Cancer 42: 195-202, 2003.
127. Zenklusen JC, Bieche I, Lidereau R, and Conti CJ. (C-A)n microsatellite repeat D7S522 is the most commonly deleted region in human primary breast cancer. Proc Natl Acad Sci USA 91: 12155-12158, 1994.
128. Zenklusen JC, Thompson JC, Klein-Szanto AJ, and Conti CJ. Frequent loss of heterozygosity in human primary squamous cell and colon carcinomas at 7q31.1: evidence for a broad range tumor suppressor gene. Cancer Res 55: 1347-1350, 1995.
129. Zenklusen JC, Thompson JC, Troncoso P, Kagan J, and Conti CJ. Loss of heterozygosity in human primary prostate carcinomas: a possible tumor suppressor gene at 7q31.1. Cancer Res 54: 6370-6373, 1994.
130. Zenklusen JC, Weitzel JN, Ball HG, and Conti CJ. Allelic loss at 7q31.1 in human primary ovarian carcinomas suggests the existence of a tumor suppressor gene. Oncogene 11: 359-363, 1995.
131. Zhang W, Razani B, Altschuler Y, Bouzahzah B, Mostov KE, Pestell RG, and Lisanti MP. Caveolin-1 inhibits epidermal growth factor-stimulated lamellipod extension and cell migration in metastatic mammary adenocarcinoma cells (MTLn3). Transformation suppressor effects of adenovirus-mediated gene delivery of caveolin-1. J Biol Chem 275: 20717-20725, 2000.
132. Zou W, McDaneld L, and Smith LM. Caveolin-1 haploinsufficiency leads to partial transformation of human breast epithelial cells. Anticancer Res 23: 4581-4586, 2003.
133. Zundel W and Giaccia A. Inhibition of the anti-apoptotic PI(3)K/Akt/ Bad pathway by stress. Genes Dev 12: 1941-1946, 1998.
134. Zundel W, Swiersz LM, and Giaccia A. Caveolin 1-mediated regulation of receptor tyrosine kinase-associated phosphatidylinositol 3-kinase activity by ceramide. Mol Cell Biol 20: 1507-1514, 2000.